Literature DB >> 20118973

Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.

Joel W Neal, Lecia V Sequist.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20118973     DOI： 10.1038/nrclinonc.2009.191

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy.

Authors:  Frances A Shepherd; Ming-Sound Tsao
Journal:  J Clin Oncol       Date:  2006-03-01       Impact factor: 44.544

2.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

Authors:  David A Eberhard; Bruce E Johnson; Lukas C Amler; Audrey D Goddard; Sherry L Heldens; Roy S Herbst; William L Ince; Pasi A Jänne; Thomas Januario; David H Johnson; Pam Klein; Vincent A Miller; Michael A Ostland; David A Ramies; Dragan Sebisanovic; Jeremy A Stinson; Yu R Zhang; Somasekar Seshagiri; Kenneth J Hillan
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

3.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

4.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

Authors:  Nick Thatcher; Alex Chang; Purvish Parikh; José Rodrigues Pereira; Tudor Ciuleanu; Joachim von Pawel; Sumitra Thongprasert; Eng Huat Tan; Kristine Pemberton; Venice Archer; Kevin Carroll
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

Review 5.  Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.

Authors:  Lecia V Sequist; Daphne W Bell; Thomas J Lynch; Daniel A Haber
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

Review 6.  Epidermal growth factor receptor mutations in lung cancer.

Authors:  Sreenath V Sharma; Daphne W Bell; Jeffrey Settleman; Daniel A Haber
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

7.  First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Authors:  Lecia V Sequist; Renato G Martins; David Spigel; Steven M Grunberg; Alexander Spira; Pasi A Jänne; Victoria A Joshi; David McCollum; Tracey L Evans; Alona Muzikansky; Georgiana L Kuhlmann; Moon Han; Jonathan S Goldberg; Jeffrey Settleman; A John Iafrate; Jeffrey A Engelman; Daniel A Haber; Bruce E Johnson; Thomas J Lynch
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

8.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

9.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245
  9 in total
  4 in total

1.  Rapid and efficient detection of EGFR mutations in problematic cytologic specimens by high-resolution melting analysis.

Authors:  Katarina Hlinkova; Pavel Babál; Peter Berzinec; Ivan Majer; Denisa Ilencikova
Journal:  Mol Diagn Ther       Date:  2011-02-01       Impact factor: 4.074

2.  Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

Authors:  C A Carter; A Rajan; C Keen; E Szabo; S Khozin; A Thomas; C Brzezniak; U Guha; L A Doyle; S M Steinberg; L Xi; M Raffeld; Y Tomita; M J Lee; S Lee; J B Trepel; K L Reckamp; S Koehler; B Gitlitz; R Salgia; D Gandara; E Vokes; G Giaccone
Journal:  Ann Oncol       Date:  2016-01-22       Impact factor: 32.976

3.  Documentation of oral versus intravenous chemotherapy plans in patients with metastatic non-small-cell lung cancer.

Authors:  Joseph A Greer; Inga T Lennes; Emily R Gallagher; Jennifer S Temel; William F Pirl
Journal:  J Oncol Pract       Date:  2014-01-28       Impact factor: 3.840

Review 4.  Lung Cancer Gene Signatures and Clinical Perspectives.

Authors:  Ruprecht Kuner
Journal:  Microarrays (Basel)       Date:  2013-12-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.